Aspirin, salicylates, and cancer

Peter C. Elwood, Alison M. Gallagher, Garry G. Duthie, Luis A. J. Mur, Gareth Morgan

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

Original languageEnglish
Pages (from-to)1301-1309
Number of pages9
JournalThe Lancet
Volume373
Issue number9671
Early online date26 Mar 2009
DOIs
Publication statusPublished - 11 Apr 2009

Keywords

  • nonsteroidal antiinflammatory drugs
  • low-dose aspirin
  • randomized controlled-trials
  • prevent colorectal adenomas
  • breast-cancer
  • colon-cancer
  • mediated apoptosis
  • sodium-salicycate
  • induced apoptosis
  • genomic instability

Cite this

Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. J., & Morgan, G. (2009). Aspirin, salicylates, and cancer. The Lancet, 373(9671), 1301-1309. https://doi.org/10.1016/S0140-6736(09)60243-9

Aspirin, salicylates, and cancer. / Elwood, Peter C.; Gallagher, Alison M.; Duthie, Garry G.; Mur, Luis A. J.; Morgan, Gareth.

In: The Lancet, Vol. 373, No. 9671, 11.04.2009, p. 1301-1309.

Research output: Contribution to journalArticle

Elwood, PC, Gallagher, AM, Duthie, GG, Mur, LAJ & Morgan, G 2009, 'Aspirin, salicylates, and cancer', The Lancet, vol. 373, no. 9671, pp. 1301-1309. https://doi.org/10.1016/S0140-6736(09)60243-9
Elwood PC, Gallagher AM, Duthie GG, Mur LAJ, Morgan G. Aspirin, salicylates, and cancer. The Lancet. 2009 Apr 11;373(9671):1301-1309. https://doi.org/10.1016/S0140-6736(09)60243-9
Elwood, Peter C. ; Gallagher, Alison M. ; Duthie, Garry G. ; Mur, Luis A. J. ; Morgan, Gareth. / Aspirin, salicylates, and cancer. In: The Lancet. 2009 ; Vol. 373, No. 9671. pp. 1301-1309.
@article{d8cd72e57b9748959d6b5ffe8463af57,
title = "Aspirin, salicylates, and cancer",
abstract = "Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.",
keywords = "nonsteroidal antiinflammatory drugs, low-dose aspirin, randomized controlled-trials, prevent colorectal adenomas, breast-cancer, colon-cancer, mediated apoptosis, sodium-salicycate, induced apoptosis, genomic instability",
author = "Elwood, {Peter C.} and Gallagher, {Alison M.} and Duthie, {Garry G.} and Mur, {Luis A. J.} and Gareth Morgan",
year = "2009",
month = "4",
day = "11",
doi = "10.1016/S0140-6736(09)60243-9",
language = "English",
volume = "373",
pages = "1301--1309",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "9671",

}

TY - JOUR

T1 - Aspirin, salicylates, and cancer

AU - Elwood, Peter C.

AU - Gallagher, Alison M.

AU - Duthie, Garry G.

AU - Mur, Luis A. J.

AU - Morgan, Gareth

PY - 2009/4/11

Y1 - 2009/4/11

N2 - Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

AB - Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefit of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

KW - nonsteroidal antiinflammatory drugs

KW - low-dose aspirin

KW - randomized controlled-trials

KW - prevent colorectal adenomas

KW - breast-cancer

KW - colon-cancer

KW - mediated apoptosis

KW - sodium-salicycate

KW - induced apoptosis

KW - genomic instability

U2 - 10.1016/S0140-6736(09)60243-9

DO - 10.1016/S0140-6736(09)60243-9

M3 - Article

VL - 373

SP - 1301

EP - 1309

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9671

ER -